Measles: Rapid Evidence Review

David S. Gregory, MD
Shefali S. Shah, MD
Brittany L. England, MD

American Family Physician. 2026;114(5):519-527.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Measles is one of the most contagious, vaccine-preventable viral infections, capable of infecting up to 90% of exposed nonimmune people. Respiratory droplets and aerosols from people infected with measles remain infectious for up to 2 hours. Infection in unvaccinated people can lead to hospitalization and death. Approximately 1 to 3 of every 1,000 children with measles will die from complications. Measles-mumps-rubella vaccination is highly safe and effective at reducing infection risk and preventing community spread. Population-based studies have found no association between vaccination and autism spectrum disorder or other neurodevelopmental disorders. Although measles has been considered eliminated in the United States since 2000, outbreaks have recently become larger and more common because vaccination rates in many states and counties have fallen below herd immunity thresholds. Symptoms include cough, coryza, conjunctivitis, and fever, followed by erythematous maculopapular exanthem. Family physicians play a key role in increasing vaccination rates and reducing risk of community spread through appropriate suspicion, early diagnostic testing, and isolation of people who are infected. Vitamin A supplementation may reduce mortality rates in hospitalized children with severe or complicated measles but should be used only under medical supervision to avoid toxicity; it should be avoided during pregnancy. Management of measles outbreaks requires isolating people who have been exposed or infected, discerning which people who were exposed have presumed immunity, and providing postexposure prophylaxis to nonimmune people with vaccination or immunoglobulin infusion.

Measles is caused by rubeola, a virus capable of infecting up to 90% of nonimmune people who have been exposed. Respiratory droplets and aerosols suspended in the air remain infectious for up to 2 hours.1 Infection rates have increased in recent years, and family physicians play a pivotal role in increasing vaccination rates and managing measles outbreaks. This review summarizes the epidemiologic trends and evidence for diagnosis, prevention, and treatment of measles.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating Comments
Measles-mumps-rubella vaccination is highly safe and the only effective way to prevent measles infections and complications in people 1 year and older who are not pregnant and are immunocompetent.7,9–14 A Large population-based outcome trials
Population-based studies have found no association between measles-mumps-rubella vaccination and autism spectrum disorder.9–14 A Large population-based outcome trials
Real-time polymerase chain reaction testing should be used to diagnose suspected measles infection and define outbreaks.23 C Small diagnostic accuracy studies
Appropriately dosed and medically supervised vitamin A supplementation may be used to reduce mortality risk in hospitalized children with severe or complicated measles. Unsupervised supplementation should be discouraged to avoid potential toxicity.24,29–32,34 B Meta-analysis of multiple studies performed outside the United States

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

EPIDEMIOLOGY

  • Before the vaccine was introduced in 1963, hundreds of measles deaths were reported annually in the United States, but by 2000, measles was considered eliminated nationwide.2,3 Measles outbreaks have been associated with international travel but since 2023 have become more common and widespread because of decreasing vaccination rates in many states and counties.2,4
  • eFigure A shows numbers of confirmed infections by state, and Figure 1 shows vaccination rates for kindergartners by county.4 The number of measles cases in the United States increased from 285 in 2024 to 2,288 (with three confirmed deaths) in 2025.2 There have been 4,080 confirmed cases in 2026 as of October 9.2
  • Approximately 1 to 3 of every 1,000 children with measles will die from complications.5
  • The Centers for Disease Control and Prevention website and Johns Hopkins University measles tracker have the most up-to-date data on cases and vaccination rates.2,6 Table 1 lists online resources for tracking and managing outbreaks.

DAVID S. GREGORY, MD, FAAFP, is the regional medical director of the Virginia Tech Carilion Family Medicine Residency Program, and a professor in the Department of Family and Community Medicine at Virginia Tech Carilion School of Medicine, Roanoke.

SHEFALI S. SHAH, MD, is a core faculty member at the Virginia Tech Carilion Family Medicine Residency Program, and an assistant professor in the Department of Family and Community Medicine at Virginia Tech Carilion School of Medicine, Roanoke.

BRITTANY L. ENGLAND, MD, is a clinical faculty member at Virginia Tech Carilion Family Medicine Residency Program, and an assistant professor in the Department of Family and Community Medicine at Virginia Tech Carilion School of Medicine, Roanoke.

Published online October 15, 2026.

Address correspondence to David S. Gregory, MD, at dgregory2@carilionclinic.org.

Author Disclosure: No relevant financial relationships.

  1. 1.Iwamura N, et al. Predicting the airborne transmission of measles: impact of indoor carbon dioxide (CO2) levels and mitigation strategies. Cureus. 2024;16(7):e64882.
  2. 2.Centers for Disease Control and Prevention. Measles cases and outbreaks. Updated October 9, 2026. Accessed October 14, 2026. https://www.cdc.gov/measles/data-research/index.html​
  3. 3.Centers for Disease Control and Prevention. Clinical overview of measles. August 5, 2026. Accessed August 30, 2026. https://www.cdc.gov/measles/hcp/clinical-overview/index.html#cdc_clinical_overview_test_dia-diagnosis-and-laboratory-testing​
  4. 4.Axios. Where vaccination rates declined the most, by county. December 31, 2025. Accessed August 30, 2026. https://www.axios.com/2025/12/31/measles-flu-vaccine-mmr-rates-2026​
  5. 5.Centers for Disease Control and Prevention. Measles symptoms and complications. August 5, 2026. Accessed August 30, 2026. https://www.cdc.gov/measles/signs-symptoms/index.html​
  6. 6.Johns Hopkins University. U.S. measles tracker. Updated October 9, 2026. Accessed October 14, 2026. https://publichealth.jhu.edu/ivac/resources/us-measles-tracker​
  7. 7.Do LAH, et al. Measles 2025. N Engl J Med. 2025;393(24):2447-2458.
  8. 8.McLean HQ; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013. MMWR Recomm Rep. 2013;62:1-34.
  9. 9.Madsen KM, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347(19):1477-1482.
  10. 10.Çatlı NE, et al. The relationship between autism and autism spectrum disorders and vaccination. Trends Pediatr. 2025;6(2):76-81.
  11. 11.Wilson K, et al. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine. Arch Pediatr Adolesc Med. 2003;157(7):628-634.
  12. 12.Zerbo O, et al. Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine. 2022;40(18):2568-2573.
  13. 13.DeStefano F, et al. The MMR vaccine and autism. Annu Rev Virol. 2019;6(1):585-600.
  14. 14.Gulati S, et al. The vaccine-autism connection: no link, still debate, and we are failing to learn the lessons. Autism. 2025;29(7):1639-1645.
  15. 15.Minta AA, et al. Progress toward measles elimination — worldwide, 2000–2023. MMWR Morb Mortal Wkly Rep. 2024;73(45):1036-1042.
  16. 16.Bester JC. Measles and measles vaccination: a review. JAMA Pediatr. 2016;170(12):1209-1215.
  17. 17.Gangar P, et al. Viral exanthems. In: Hoeger PH, et al., eds. Harper's Textbook of Pediatric Dermatology, 4th ed. John Wiley & Sons, Inc. 2019; 660–680.
  18. 18.Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708-1733.
  19. 19.Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-770.
  20. 20.National Health Service. Scarlet fever. December 23, 2024. Accessed August 30, 2026. www.nhs.uk/conditions/scarlet-fever​
  21. 21.Centers for Disease Control and Prevention. Photos of measles. May 23, 2024. Accessed August 30, 2026. https://www.cdc.gov/measles/signs-symptoms/photos.html​
  22. 22.Hübschen JM, et al. Measles. Lancet. 2022;399(10325):678-690.
  23. 23.Roy F, et al. Rapid identification of measles virus vaccine genotype by real-time PCR. J Clin Microbiol. 2017;55(3):735-743.
  24. 24.Committee on Infectious Diseases. Kimberlin DW, ed. RedBook: 2024–2027 Report of the Committee on Infectious Diseases, 33rd ed. American Academy of Pediatrics; 2024.
  25. 25.Centers for Disease Control and Prevention. CDC Stacks: measles prevention and treatment overview. May 1, 2026. Accessed August 30, 2026. https://stacks.cdc.gov/view/cdc/257236​
  26. 26.Moss WJ. Measles. Lancet. 2017;390(10111):2490-2502.
  27. 27.Papanikolopoulou A, et al. Measles: a narrative review of current therapeutic options and implications for the future. Viruses. 2026;18(8):816.
  28. 28.Bichon A, et al. Case report: ribavirin and vitamin A in a severe case of measles. Medicine (Baltimore). 2017;96(50):e9154.
  29. 29.Imdad A, et al. Vitamin A supple menta tion for preventing morbidity and mortality in children from six months to five years of age. Cochrane Database Syst Rev. 2022(3):CD008524.
  30. 30.Vitamin A supplements: a guide to their use in the treatment and prevention of vitamin A deficiency and xerophthalmia, 2nd ed. World Health Organization; 1997. Accessed August 30, 2026. https://iris.who.int/bitstream/handle/10665/41947/9241545062.pdf​
  31. 31.National Foundation for Infectious Diseases. Call to action: vitamin A for the management of measles in the United States. March 2020. Accessed August 30, 2026. https://www.nfid.org/wp-content/uploads/2023/04/Call-to-Action-Vitamin-A-for-the-Management-of-Measles-in-the-US-FINAL.pdf​
  32. 32.Bastos Maia S, et al. Vitamin A and pregnancy: a narrative review. Nutrients. 2019;11(3):681.
  33. 33.Olson JM, et al. Vitamin A toxicity. StatPearls. Updated September 2, 2023. Accessed May 8, 2026. http://www.ncbi.nlm.nih.gov/books/NBK532916​
  34. 34.Suchdev PS, et al. Reevaluating vitamin A for measles management in high-income settings. Lancet Reg Health Am. 2025;48:101168.
  35. 35.Centers for Disease Control and Prevention. Expanding measles outbreak in the United States and guidance for the upcoming travel season. March 7, 2025. Accessed May 8, 2026. https://www.cdc.gov/han/php/notices/han00522.html​
  36. 36.Centers for Disease Control and Prevention. Healthcare providers: stay alert for measles cases. January 26, 2026. Accessed May 8, 2026. https://www.cdc.gov/measles/hcp/clinical-overview/stay-alert-for-measles-cases.html​
  37. 37.Council of State and Territorial Epidemiologists. 24/7 table. Accessed August 30, 2026. https://libraries.cste.org/24-7-table
  38. 38.Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for measles in healthcare settings. August 19, 2025. Accessed August 30, 2026. https://www.cdc.gov/infection-control/hcp/measles/index.html​
  39. 39.Campos-Outcalt D. Practice alert: measles continues to be a threat to health in the United States. Am Fam Physician. 2024;110(2):120-121.
  40. 40.Centers for Disease Control and Prevention. Measles. April 5, 2024. Accessed September 8, 2026. https://www.cdc.gov/infection-control/hcp/healthcare-personnel-epidemiology-control/measles.html​
  41. 41.Stein-Zamir C, et al. Measles clinical presentation, hospitalization and vaccination status among children in a community-wide outbreak. Vaccine. 2023;41(17):2764-2768.
  42. 42.van Dam ASG, et al. Effect of vaccination on severity and infectiousness of measles during an outbreak in the Netherlands, 2013–2014. Epidemiol Infect. 2020;148:e81.
  43. 43.Au S, et al. Measles: an updated literature review of the host response, pathogenesis, complications, prevention measures, and recent outbreaks. Curr Issues Mol Biol. 2026;48(2):206.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.